嵌合抗原受体T细胞疗法治疗中枢系统血液恶性肿瘤的研究进展  

Progress in the study of CAR-T cell therapy in the treatment of hematological tumors of central nervous system

作　　者：刘一帆 刘碧若 靖彧[1] LIU Yifan;LIU Biruo;JING Yu(Department of Hematology,the First Medical Center,the Chinese People's Liberation Army General Hospital,Beijing,100853,China;Department of Gynecology,the Third People's Hospital of Kunming)

机构地区：[1]解放军总医院第一医学中心血液科,北京100853 [2]昆明市第三人民医院妇产科

出　　处：《临床血液学杂志》2024年第7期524-528,共5页Journal of Clinical Hematology

摘　　要：中枢神经系统(central nervous system,CNS)是血液系统恶性肿瘤常见的髓外侵犯部位,且往往与不良预后密切相关,然而现有疗法及疗效远不能满足需求。嵌合抗原受体T(CAR-T)细胞疗法在国内外血液肿瘤的治疗中已表现出较大优势,但由于其治疗不良反应存在神经毒性风险,使得治疗中枢系统血液肿瘤仍饱受争议。因此,文章针对国内外部分CAR-T疗法治疗中枢系统血液肿瘤的研究做一综述,探讨此疗法用于治疗中枢血液肿瘤的可能性、安全性及有效性,为临床工作提供参考,以期提高中枢系统血液肿瘤患者的缓解率与生存率。The central nervous system(CNS)is a common site of extramedullary invasion by hematological malignant tumors,and the involvement of the CNS is often closely related to poor prognosis.However,the existing therapies and their curative effects are far from meeting the needs.CAR-T cell therapy has shown great advantages in the treatment of hematological tumors at home and abroad,but the treatment of CNS hematological tumors has been controversial due to the risk of neurotoxicity.Therefore,this article reviews some of the studies on CAR-T in the treatment of CNS hematological tumors,and discusses the possibility,safety and efficacy of the therapy in the treatment of CNS hematological tumors.The purpose is to provide a reference for clinical work and improve the remission rate and survival rate of such patients.

关 键 词：嵌合抗原受体T细胞 中枢神经系统 血液系统恶性肿瘤 

分 类 号：R733.7[医药卫生—肿瘤]